Alpha 2.0
Login Register
» Authors » Andrew Barbour

Andrew Barbour

Explore the profile of Andrew Barbour including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 48
Citations 6062
Followers 0
Related Specialties
Oncology
General Surgery
Science
Top 10 Co-Authors
B Mark Smithers
Janine Thomas
Brendon J Coventry
John F Thompson
Felicity Newell
Ann-Marie Patch
James G Kench
Christopher J Scarlett
Krishna Epari
Rita T Lawlor
Published In
Nature
Ann Surg Oncol
J Surg Oncol
Eur J Surg Oncol
BMC Cancer
Affiliations
Soon will be listed here.
Recent Articles
11.
C5b-9 Membrane Attack Complex Formation and Extracellular Vesicle Shedding in Barrett's Esophagus and Esophageal Adenocarcinoma
Kolka C, Webster J, Lepletier A, Winterford C, Brown I, Richards R, et al.
Front Immunol . 2022 Mar; 13:842023. PMID: 35345676
The early complement components have emerged as mediators of pro-oncogenic inflammation, classically inferred to cause terminal complement activation, but there are limited data on the activity of terminal complement in...
12.
AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer
Oar A, Lee M, Le H, Wilson K, Aiken C, Chantrill L, et al.
BMC Cancer . 2021 Aug; 21(1):936. PMID: 34412605
Background: Among patients with non-metastatic pancreatic cancer, 80% have high-risk, borderline resectable or locally advanced cancer, with a 5-year overall survival of 12%. MASTERPLAN evaluates the safety and activity of...
13.
Human CD141 dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model
Lee Y, OBrien L, Walpole C, Pearson F, Leal-Rojas I, Masterman K, et al.
J Immunother Cancer . 2021 Mar; 9(3). PMID: 33737342
Background: The conventional type 1 dendritic cell subset (cDC1) is indispensable for tumor immune responses and the efficacy of immune checkpoint inhibitor (ICI) therapies in animal models but little is...
14.
Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study
Kenyon-Smith T, Kroon H, Miura J, Teras J, Beasley G, Mullen D, et al.
Eur J Surg Oncol . 2020 Aug; 46(11):2140-2146. PMID: 32739218
Introduction: Isolated limb infusion (ILI) is a minimally-invasive procedure for delivering high-dose regional chemotherapy to treat melanoma in-transit metastases confined to a limb. The aim of this international multi-centre study...
15.
Opioid-induced Somatic Activation: Prevalence in a Population of Patients With Chronic Pain
Barbour A, Asbury M, Riordan P, Webb J, Prakken S
Cureus . 2020 Jun; 12(5):e7911. PMID: 32494526
Context and objective Opioids have heterogeneous side effects including a well-known effect of sedation; however, the opposing effect of stimulation, or somatic activation, has been largely ignored or overlooked. The...
16.
Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty
Roy A, Shapiro J, Burge M, Karapetis C, Pavlakis N, Segelov E, et al.
Expert Rev Anticancer Ther . 2020 Mar; 20(4):305-324. PMID: 32202178
: A multimodal approach in operable early-stage oesophago-gastric (OG) cancer has evolved in the last decade, leading to improvement in overall outcomes.: A review of the published literature and conference...
17.
International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients
Teras J, Kroon H, Miura J, Kenyon-Smith T, Beasley G, Mullen D, et al.
Ann Surg Oncol . 2020 Mar; 27(5):1420-1429. PMID: 32152775
Background: Isolated limb infusion (ILI) is used to treat in-transit melanoma metastases confined to an extremity. However, little is known about its safety and efficacy in octogenarians and nonagenarians (ON)....
18.
Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT)
Oar A, Lee M, Le H, Hruby G, Dalfsen R, Pryor D, et al.
Pract Radiat Oncol . 2019 Nov; 10(3):e136-e146. PMID: 31761541
Purpose: Nonrandomized data exploring pancreas stereotactic body radiation therapy (SBRT) has demonstrated excellent local control rates and low toxicity. Before commencing a randomized trial investigating pancreas SBRT, standardization of prescription...
19.
Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study
Kroon H, Coventry B, Henderson M, Barbour A, Serpell J, Smithers B, et al.
Eur J Surg Oncol . 2019 Mar; 45(5):832-837. PMID: 30867095
Background: Isolated limb infusion (ILI) is a minimally invasive treatment for patients with locally advanced extremity melanoma. Most studies combine results of upper-limb ILI (UL-ILI) and lower-limb ILI (LL-ILI), leaving...
20.
Patients with in-transit melanoma metastases have comparable survival outcomes following isolated limb infusion or intralesional PV-10-A propensity score matched, single center study
Read T, Fayers W, Thomas J, Wagels M, Barbour A, Smithers B
J Surg Oncol . 2019 Jan; 119(6):717-727. PMID: 30644564
Background And Objective: Isolated limb infusion (ILI) and intralesional PV-10 are well described locoregional therapies for in-transit melanoma. The objective of this study was to assess the effect of these...